Objectives: Fetal fibronectin (fFN) testing between the 24th and 34th weeks of pregnancy in patients with symptomatic preterm labor (PTL) helps assess the risk of spontaneous preterm birth (sPTB), yet ...

A new diagnostic test offered earlier in pregnancy could help doctors determine if mothers-to-be are at risk of giving birth prematurely. The study was published in Obstetrics and Gynecology. In ...

May 28, 2010 (San Francisco, California) — A new disposable measuring probe called CerviLenz, designed to measure vaginal cervical length, is as effective as fetal fibronectin in assessing risk for ...

Please can you give an overview of the causes of preterm labor. Preterm birth is the most significant issue facing pregnant women and the clinicians caring for them. With each preterm delivery, a ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--April 28, 2005--Adeza (Nasdaq:ADZA) announced today that it has branded its proprietary test for fetal fibronectin (fFN) as FullTerm(TM), The Fetal Fibronectin Test ...

Expectant mothers, listen up. There is a simple test to detect a risk for premature birth. Dr Bruce Hensel has the exclusive story. "This is life saving information; because premature delivery raises ...

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. Lumos achieves first milestone in second phase of its development agreement to develop a new foetal ...

One in five pregnant women has her labor induced. The question: Did the doctor pick the best time to try to speed nature’s course, or would waiting a few more days make for an easier delivery? A ...

WASHINGTON -- One in five pregnant women has her labor induced. The question: Did the doctor pick the best time to try to speed nature's course, or would waiting a few more days make for an easier ...

A simple test can help reliably determine whether signs of an imminent premature delivery are likely to result in a false alarm, research suggests. Less than half of women showing these signs actually ...

There is a need to develop blood-based bioassays for breast cancer (BC) screening. In this study, differential gene expression between BC samples and benign tumours was used to identify candidate ...